Tofacitinib Citrate CAS 477600-75-2 Chemical Intermediates

Product Description:

Product Name: Tofacitinib citrate CAS NO: 477600-75-2                                       

Synonyms:

(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-p-iperidinepropanenitrile;

Tofacitinib;

Tasocitinib;

Chemical & Physical Properties:

Appearance: Pale powder

Assay :≥99.0%

Density: 1.296g/cm3

Boiling Point: 585.845℃ at 760 mmHg

Flash Point: 308.108℃

Refractive Index: 1.646

Vapor Pressure: 0.0±1.6 mmHg at 25℃

Safety Information:

HS Code: 29335990

Signal Word: Warning

Hazard Statements: H315; H319; H335

Precautionary Statements:

P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

CP-690550 is a pyrrolo[2,3-d]pyrimidine derivative, as Janus kinase inhibitor for treatment of rheumatoid arthritis.

The chemical system name of Tofacitinib citrate is 3-{(3R, 4R) -4-methyl-3 -[methyl -(7H-pyrronozo [2,3-d] pyrimidine-4-yl) -p-iperidine-1-yl] -3-oxo-propionitrile citrate, Chemicalbook is a Janus kinase inhibitor developed by Pfizer (USA). On November 6, 2012, the U.S. Food and Drug Administration (FDA) approved the drug for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response or intolerance to methotrexate therapy. Tofatib is indicated for adult patients with moderately to severely active rheumatoid arthritis (RA) who have inadequate or intolerant MTX response and may be used in combination with MTX or other abiotic ameliorating antirheumatic agents (DMARDs).

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.